Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ESSENCE (part 1)

ESSENCE (part 1)

Semaglutide · MASH F2–F3

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
MASH F2–F3
Participants
800
Duration
72 weeks

Outcomes in the indication

ESSENCE (part 1) Semaglutide · MASH F2–F3 · 72 weeks · n = 800 seed

Steatohepatitis resolution 62.9 % vs 34.3 %; fibrosis improvement 36.8 % vs 22.4 %; FDA accelerated approval 2025

MeasureDrugControlDifference (95 % CI)Status
Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis
week 72
+36.8+22.4+14.4 (+7.5 to +21.3) percentage pointsverified
Resolution of steatohepatitis without worsening of fibrosis
week 72
+62.9+34.3+28.7 (+21.1 to +36.2) percentage pointsverified
Verbatim quotes (2)
  • Reduction in liver fibrosis (>=1 stage) without worsening of steatohepatitis
    A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001)
  • Resolution of steatohepatitis without worsening of fibrosis
    Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ESSENCE (part 1). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/essence/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.